title: Antipsychotic-like effect of trimetazidine in a rodent model.
abstract: Trimetazidine (TMZ) has been used as an anti-ischemic agent for angina pectoris, chorioretinal disturbances, and vertigo. Also, it can induce extrapyramidal type adverse reaction such as parkinsonism, gait disorder, and tremor via blockade of D2 receptors. In the present study, we evaluated the effect of TMZ on novelty-induced rearing behavior and apomorphine-induced stereotypy behavior in male rats. Four groups of rat (n = 7) were administrated with TMZ (10 and 20 mg/kg, i.p.), chlorpromazine (1 mg/kg, i.p.), or isotonic saline. One hour later, apomorphine (2 mg/kg, s.c.) was administrated to each rat. Our results showed that both doses of TMZ significantly decreased the rearing behavior in rats, whereas the decrease with chlorpromazine was higher. TMZ also decreased the stereotypy scores in a dose-dependent manner. We concluded that TMZ has beneficial effects on rearing behavior and stereotypy, which are accepted to be indicators of antipsychotic effect. Taken together, with its antioxidative and cytoprotective properties, TMZ is worthy of being investigated for its anti-psychotic effects as a primary or an adjunctive drug.
authors.affiliation: Gaziosmanpaşa University School of Medicine, Department of Physiology, 60100 Tokat, Turkey.
authors.forename: Oytun
authors.initials: O
authors.lastname: Erbaş
authors.forename: Hüseyin Serdar
authors.initials: HS
authors.lastname: Akseki
authors.forename: Betül
authors.initials: B
authors.lastname: Eliküçük
authors.forename: Dilek
authors.initials: D
authors.lastname: Taşkıran
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001058:Apomorphine; D004195:Disease Models, Animal; D018491:Dopamine Agonists; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D011605:Psychoses, Substance-Induced / Q000188:drug therapy* / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013239:Stereotyped Behavior / Q000187:drug effects* / Q000502:physiology*; D016896:Treatment Outcome; D014292:Trimetazidine / Q000008:administration & dosage*
chemical_list: D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D001058:Apomorphine; D014292:Trimetazidine